Shanghai Securities News www.cnstock.com, On November 25th that AIM Vaccine announced that the company held an Investor Open Day on November 21st. CITIC Securities, Guotai Junan, Shenwan Hongyuan, Huaxin Securities, and 57 other securities firms and institutional investors, as well as some industry experts, visited AIM's modern production base in Ningbo to have discussions and exchanges with the management.

Participants visited the mRNA vaccine intelligent workshop, iterative series rabies vaccine intelligent workshop, iterative series pneumonia vaccine intelligent workshop, combined vaccine intelligent workshop, and quadrivalent conjugate meningitis intelligent workshop of AIM's wholly-owned subsidiary.

The company's management introduced to institutional investors the clinical data and latest progress of the upcoming 13-valent conjugate pneumonia vaccine, serum-free iterative rabies vaccine, and 23-valent pneumonia polysaccharide vaccine. Among them, the 13-valent conjugate pneumonia vaccine has obtained a production license, and the market registration has been accepted; the serum-free iterative rabies vaccine has submitted a pre-application for market registration. At the same time, the iterative pneumonia vaccine series, iterative rabies vaccine series, iterative influenza vaccine series, and mRNA major single-item vaccine series were introduced. Among them, the mRNA major single-item vaccine series, especially the mRNA shingles vaccine and mRNA RSV vaccine, have received high attention from institutional investors and widespread recognition from industry experts due to their excellent trial data.

In response to the question of whether rabies vaccines and hepatitis B vaccines will join the price war, AIM Vaccine stated that the first thing to clarify is that the vaccine market has not formed a price reduction trend at present, and it is only the price reduction of special varieties, which will not form a trend of full industry and full variety follow-up. The particularity of the two vaccines, rabies vaccine and hepatitis B vaccine, determines that the vaccine price is not the primary consideration, and the vaccinators are more concerned about the safety of the vaccine rather than its economic nature.

In terms of the company's overseas strategic layout, AIM introduced that currently, the company's rabies vaccines, meningitis vaccines, and other products have been exported to Egypt, Tajikistan, Ghana, Pakistan, and other countries. The future export path, on the one hand, is to obtain the PQ certification from the World Health Organization (WHO), and the company's 13-valent conjugate pneumonia vaccine, quadrivalent meningitis vaccine, etc., are included in the medium and high priority certification products, which have advantages.

At the same time, within the next three years, the company is expected to have more than two new products registered and launched each year. After these new products are launched, they will consider registration in both domestic and overseas markets, hoping that the domestic and overseas markets will each account for 50% in the future.

AIM stated that the company has a clear plan for equity incentive and share repurchase, and will launch it at the right time. The company will actively promote the listing on the A-share STAR Market according to the established plan, based on the progress of new product launches and the situation of the securities market.